Cover Image
市場調查報告書

EpiCast Report:裘馨氏肌肉萎縮症的流行病學的預測

EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 328421
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:裘馨氏肌肉萎縮症的流行病學的預測 EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2023
出版日期: 2015年03月16日 內容資訊: 英文 58 Pages
簡介

裘馨氏肌肉萎縮症 (DMD) 及貝克氏肌肉萎縮症 (BMD) 都是一種絕症,是惡化性的肌肉萎縮症。全球主要6個國家DMD確診的患病人數2013年達到17,675人,預測2023年將達到17,712人。尤其是5∼13歲的患病人數2013年為6,076人,預測2023年將達到6,250人。此外,無義突變的DMD患病人數 (確診,全年齡) 推算2013年為2,260人,預測2023年將達到2,264人。

本報告提供全球主要6個國家(美國·德國·法國·義大利·西班牙·英國)的裘馨氏肌肉萎縮症 (以下簡稱DMD) 的發病情形與今後預測相關分析,提供您DMD的特徵和各國的詳細情況,今後10年的患病人數預測值等調查評估。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 預定出版的相關調查報告

第3章 流行病學

  • 疾病的背景
  • 風險要素與併發症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件
  • DMD的流行病學的預測 (今後11年份)
    • DMD已診斷的患病人數 (全年齡)
    • DMD已診斷的患病人數 (5∼13歲)
    • DMD已診斷的患病人數:各年齡 (全年齡)
    • DMD已診斷的患病人數 (年齡已調整的)
  • DMD的無義突變的流行病學的預測 (今後11年份)
  • DMD外顯子Skipping Therapy的適用可能性的流行病學的預測 (今後11年份)
    • 成為外顯子51Skipping Therapy的使用對象,DMD已診斷的患病人數 (全年齡)
    • 成為外顯子45Skipping Therapy的使用對象,DMD已診斷的患病人數 (全年齡)
    • 成為外顯子53Skipping Therapy的使用對象,DMD已診斷的患病人數 (全年齡)
    • 成為外顯子44Skipping Therapy的使用對象,DMD已診斷的患病人數 (全年齡)
  • 貝克氏肌肉萎縮症 (BMD) 的流行病學的預測 (今後11年份)
    • BMD已診斷的患病人數 (全年齡)
    • BMD的各年齡確診的患病人數 (全年齡)
    • BMD已診斷的患病人數 (年齡已調整的)
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER077-15

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are rare progressive muscle wasting disorders.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of DMD (all ages) in the 6MM will increase from 17,675 diagnosed prevalent cases in 2013 to 17,712 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 0.02%. The 6MM had an estimated 6,076 diagnosed prevalent cases of DMD for ages 5-13 years in 2013, and the number of diagnosed prevalent cases is expected to increase to 6,250 by 2023, at an AGR of 0.29%. GlobalData epidemiologists forecast that the diagnosed prevalent cases of DMD with nonsense mutations (all ages) in the 6MM will increase from 2,260 diagnosed prevalent cases in 2013 to 2,264 diagnosed prevalent cases in 2023, at an AGR of 0.02%.

GlobalData epidemiologists used the best available data from peer-reviewed journal articles and national DMD mutation databases to arrive at a meaningful and in-depth analysis of the diagnosed prevalent cases of DMD and BMD for men in the 6MM based on: a confirmed deletion, duplication, or point mutation in the DMD gene; reduced or absent dystrophin immunolabeling; or cases fulfilling "definite" or "probable" criteria of the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet). For all the 6MM, the diagnosed prevalent cases of DMD and BMD were segmented by age, which facilitates an understanding of the distribution of the disease within the population, and informs strategies to improve the management of the disease. The diagnosed prevalent cases of DMD in each of the 6MM were further segmented by therapeutically significant populations including the applicability of exon skipping therapies (exons 51, 45, 53, and 44), nonsense mutations, and cases ages 5-13 years in these markets.

Scope

  • The Duchenne Muscular Dystrophy (DMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for DMD in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DMD and Becker Muscular Dystrophy (BMD) in men, segmented by age (in 10-year age groups beginning at 0 years and ending at =40 years for cases of DMD with a special focus on the subgroup of ages 5-13 years, and in 15-year age groups beginning at 0 years and ending at =75 years for cases of BMD) in these markets. Additionally, the diagnosed prevalent cases of DMD (all ages) are further segmented by the applicability of exon skipping therapies (exons 51, 45, 53, and 44) and nonsense mutations.
  • The DMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global DMD market.
  • Quantify patient populations in the global DMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for DMD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for DMD (2013-2023)
    • 3.5.1. Diagnosed Prevalent Cases of DMD (All Ages)
    • 3.5.2. Diagnosed Prevalent Cases of DMD (Ages 5-13 Years)
    • 3.5.3. Age-Specific Diagnosed Prevalent Cases of DMD (All Ages)
    • 3.5.4. Age-Standardized Diagnosed Prevalence of DMD
  • 3.6. Epidemiological Forecast for Nonsense Mutations in DMD (2013-2023)
  • 3.7. Epidemiological Forecast for the Applicability of Exon Skipping Therapies in DMD (2013-2023)
    • 3.7.1. Diagnosed Prevalent Cases of DMD Eligible for an Exon 51 Skipping Therapy (All Ages)
    • 3.7.2. Diagnosed Prevalent Cases of DMD Eligible for an Exon 45 Skipping Therapy (All Ages)
    • 3.7.3. Diagnosed Prevalent Cases of DMD Eligible for an Exon 53 Skipping Therapy (All Ages)
    • 3.7.4. Diagnosed Prevalent Cases of DMD Eligible for an Exon 44 Skipping Therapy (All Ages)
  • 3.8. Epidemiological Forecast for BMD (2013-2023)
    • 3.8.1. Diagnosed Prevalent Cases of BMD (All Ages)
    • 3.8.2. Age-Specific Diagnosed Prevalent Cases of BMD (All Ages)
    • 3.8.3. Age-Standardized Diagnosed Prevalence of BMD
  • 3.9. Discussion
    • 3.9.1. Epidemiological Forecast Insight
    • 3.9.2. Limitations of the Analysis
    • 3.9.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for DMD and BMD
  • Table 2: Global Estimates for the Diagnosed Prevalence of DMD and BMD
  • Table 3: MD STARnet Case Definition Criteria for DMD and BMD
  • Table 4: Sources of Epidemiological Data Used for the Forecast for the Diagnosed Prevalent Cases of DMD in the 6MM
  • Table 5: Sources of Epidemiological Data Used for the Forecast for the Diagnosed Prevalent Cases of BMD in the 6MM
  • Table 6: Sources of Epidemiological Data Used for the Forecast for the Diagnosed Prevalent Cases of DMD with Nonsense Mutations in the 6MM
  • Table 7: Sources of Epidemiological Data Used for the Forecast for the Diagnosed Prevalent Cases of DMD Eligible for Exon Skipping Therapies (Exons 51, 45, 53, or 44) in the 6MM
  • Table 8: 6MM, Diagnosed Prevalent Cases of DMD, Males, All Ages, N, Select Years 2013-2023
  • Table 9: 6MM, Diagnosed Prevalent Cases of DMD, Males, Ages 5-13 Years, N, Select Years 2013-2023
  • Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of DMD, Men, N (Row %), 2013
  • Table 11: 6MM, Diagnosed Prevalent Cases of DMD with Nonsense Mutations, Males, All Ages, N, Select Years 2013-2023
  • Table 12: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 51 Skipping Therapy, Males, All Ages, N, Select Years 2013-2023
  • Table 13: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 45 Skipping Therapy, Males, All Ages, N, 2013-2023
  • Table 14: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 53 Skipping Therapy, Males, All Ages, N, Select Years 2013-2023
  • Table 15: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 44 Skipping Therapy, Males, All Ages, N, Select Years 2013-2023
  • Table 16: 6MM, Diagnosed Prevalent Cases of BMD, Males, All Ages, N, Select Years 2013-2023
  • Table 17: 6MM, Age-Specific Diagnosed Prevalent Cases of BMD, Men, N (Row %), 2013

List of Figures

  • Figure 1: Patient Flow for the Epidemiological Forecast of DMD in the 6MM
  • Figure 2: 6MM, Diagnosed Prevalent Cases of DMD, Males, All Ages, N, 2013-2023
  • Figure 3: 6MM, Diagnosed Prevalent Cases of DMD, Males, Ages 5-13 Years, N, 2013-2023
  • Figure 4: 6MM, Age-Specific Diagnosed Prevalent Cases of DMD, Men, N, 2013
  • Figure 5: 6MM, Age-Standardized Diagnosed Prevalence of DMD (Cases per 100,000 Population), All Ages, Men, 2013
  • Figure 6: 6MM, Diagnosed Prevalent Cases of DMD with Nonsense Mutations, Males, All Ages, N, 2013-2023
  • Figure 7: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 51 Skipping Therapy, Males, All Ages, N, 2013-2023
  • Figure 8: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 45 Skipping Therapy, Males, All Ages, N, 2013-2023
  • Figure 9: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 53 Skipping Therapy, Males, All Ages, N, 2013-2023
  • Figure 10: 6MM, Diagnosed Prevalent Cases of DMD Eligible for an Exon 44 Skipping Therapy, Males, All Ages, N, 2013-2023
  • Figure 11: 6MM, Diagnosed Prevalent Cases of BMD, Males, All Ages, N, 2013-2023
  • Figure 12: 6MM, Age-Specific Diagnosed Prevalent Cases of BMD, Men, N, 2013
  • Figure 13: 6MM, Age-Standardized Diagnosed Prevalence of BMD (Cases per 100,000 Population), All Ages, Men, 2013
Back to Top